Is CytoMed Therapeutics Ltd (GDTC) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 3.8% / 30% | 40.3% / 30% | 1.0% / 30% | 457.07% / 5% | ✗ NOT HALAL |
| DJIM | 3.8% / 33% | 40.3% / 33% | 1.0% / 33% | 457.07% / 5% | ✗ NOT HALAL |
| MSCI | 4.6% / 33% | 49.4% / 33% | 1.2% / 33% | 457.07% / 5% | ✗ NOT HALAL |
| S&P | 3.8% / 33% | 40.3% / 33% | 1.0% / 33% | 457.07% / 5% | ✗ NOT HALAL |
| FTSE | 4.6% / 33% | 49.4% / 33% | 1.2% / 50% | 457.07% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 92.5% | |
| Operating Margin | -452.2% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -42.3% | |
| Return on Assets (ROA) | -22.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$3M |
| Free Cash Flow | -$4M |
| Total Debt | $463,250 |
| Debt-to-Equity | 6.8 |
| Current Ratio | 5.8 |
| Total Assets | $10M |
Price & Trading
| Last Close | $1.03 |
| 50-Day MA | $1.01 |
| 200-Day MA | $1.70 |
| Avg Volume | 603K |
| Beta | -0.3 |
|
52-Week Range
$0.73
| |
About CytoMed Therapeutics Ltd (GDTC)
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company also has Business & Research Collaboration Agreement with SunAct Cancer Institute Private Limited to conduct clinical trials for the GMP grade CTM-GDT. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is CytoMed Therapeutics Ltd (GDTC) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), CytoMed Therapeutics Ltd is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is CytoMed Therapeutics Ltd's debt ratio?
CytoMed Therapeutics Ltd's debt ratio is 3.8% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 4.6%.
What are CytoMed Therapeutics Ltd's key financial metrics?
CytoMed Therapeutics Ltd has a market capitalization of $12M, and revenue of $69,501. Return on equity stands at -42.3%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.